Michael J. Acarregui, MD
Research Profile
Contact Information:
Office Tel: (319) 356-1161
Fax: (319) 356-4685
E-mail: michael-acarregui@uiowa.edu
Education and Training:
Predoctoral and Doctoral Education
1977-81, BA, Robert D. Clark Honors College, University of Oregon, Eugene, OR
1981-85, MD, Oregon Health Sciences University, Portland, OR
Postgraduate Medical Education
1985, Pediatric Internship, University of Texas Southwestern Medical Center, Dallas, Texas
1986, Pediatric Residency, University of Texas Southwestern Medical Center, Dallas, Texas
1988, Postdoctoral Fellow, Neonatal-Perinatal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas
Research Interests:
- Oxygen as a growth factor in developing fetal lung
- Capillary development in the fetal lung
- Mechanisms regulating development of the air-blood barrier
- Role of angiogenic factors in the development of chronic lung disease
- Acute and long-term outcomes of prematurely born infants
- Clinical process improvement resulting in quality improvement in the care of ill newborns
|
|
Affiliations:
Model System:
My background is in the basic science of lung development: specifically, development of the pulmonary capillary bed and the air-blood barrier. I have employed animals and human tissue and cell culture systems for this work.
I have directed the High Risk Infant Follow-Up program for the past several years and I initiated our institutional involvement in the Vermont Oxford Network (VON) in 1999. Each program includes a significant data gathering and organizing effort. Our VON participation enables us to compare our VLBW outcomes with other similar institutions and to the VON network as a whole. Our extensive database regarding the outcomes of our NICU patients is a rich source of information available for outcomes research.
The Special Care Nurseries provide an excellent laboratory for research regarding clinical outcomes management and improvement.
Recent Publications:
- Acarregui MJ, England KM, Richman JT, and Littig. Characterization of CD34+ Cells Isolated from Human Fetal Lung. Am J Physiol Lung Cell Mol Physiol 2003 284: L395--L401.
- Thomas CP, Husted RF, Campbell JR, Littig J, Acarregui MJ. Cyclic AMP-Stimulated Na+ Transport in Fetal lung Explants and in Fetal Distal Lung Epithelial Cells: Role of PKA, PI-3K, and SGK1. Am J Respir Crit Care Med. 2003; 167(7):A394.
- Acarregui MJ, Richman JT, Littig JL. Erythropoietin Increases SP-A Protein Levels and Capillary Endothelial Cell Proliferation in Human Fetal Lung In Vitro. Pediatr Res. 2003; 53(4):35A.
- Acarregui MJ, Richman JT, Littig JL. Erythropoietin Promotes Human Fetal Lung Development In Vitro. Pediatr Res. 2003; 54(4):581.
- Acarregui MJ, Eastman DL, Breitbach KC, Schuelke SK, Yankowitz J, Bell EF. The impact of aggressive medical care on the outcomes orf profoundly premature infants (23-24 weeks). Pediatr Res. 2004; 55(4): 483A.
- Cho SJ, George CS, Snyder JM, Acarregui MJ. SU1498 Inhibits alveolarization in newborn mice. Pediatr Res. 2004; 56(4): 667.
|
